Mitochondrial dysfunction in Parkinson's disease

Journal of Neurochemistry

Volumn , Issue , 2016, Pages 216-231

  Bose, Anindita ^a   Beal, M Flint ^a  

^a FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

Author keywords

DJ1; HTRA2; MAM; PINK1; VPS35; synuclein

Indexed keywords

ALPHA SYNUCLEIN; BEZAFIBRATE; CALCIUM CHANNEL STIMULATING AGENT; FUMARIC ACID DIMETHYL ESTER; GUANOSINE TRIPHOSPHATASE; INOSINE; ISRAPIDINE; MITOCHONDRIAL DNA; MITOQUIDONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PARKIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PIOGLITAZONE; PROTEIN BCL 2; SIRTUIN 1; UBIDECARENONE; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOPHAGY; CAUSAL ATTRIBUTION; CELL LOSS; COGNITION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA POLYMORPHISM; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ELECTRON TRANSPORT; ENDOPLASMIC RETICULUM; GENE; GENE FREQUENCY; GENE LOCATION; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LRRK2 GENE; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PINK1 GENE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

EID: 85027917509     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13731     Document Type: Review

References (141)

1. Ahmad T., Aggarwal K., Pattnaik B. et al. (2013) Computational classification of mitochondrial shapes reflects stress and redox state. Cell Death Dis. 4, e461.
2. Ahuja M., Ammal Kaidery N., Yang L. et al. (2016) Distinct Nrf2 signaling mechanisms of fumaric acid esters and their role in neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced experimental Parkinson's-like disease. J. Neurosci. 36, 6332–6351.
3. Alavian K. N., Beutner G., Lazrove E. et al. (2014) An uncoupling channel within the c-subunit ring of the F1FO ATP synthase is the mitochondrial permeability transition pore. Proc. Natl Acad. Sci. USA 111, 10580–10585.
4. Al-Radaideh A. M. and Rababah E. M. (2016) The role of magnetic resonance imaging in the diagnosis of Parkinson's disease: a review. Clin. Imaging 40, 987–996.
5. Andersen A. D., Binzer M., Stenager E. and Gramsbergen J. B. (2016) Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review. Acta Neurol. Scand. PMID: 26991855 DOI: 10.1111/ane.12590. [Epub ahead of print]
6. Andres-Mateos E., Perier C., Zhang L. et al. (2007) DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc. Natl Acad. Sci. USA 104, 14807–14812.
7. Beal M. F. (2005) Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58, 495–505.
8. Beal M. F., Oakes D., Shoulson I. et al. (2014) A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 71, 543–552.
9. Bender A., Krishnan K. J., Morris C. M. et al. (2006) High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 38, 515–517.
10. Berthet A., Margolis E. B., Zhang J. et al. (2014) Loss of mitochondrial fission depletes axonal mitochondria in midbrain dopamine neurons. J. Neurosci. 34, 14304–14317.
11. Bertolin G., Ferrando-Miguel R., Jacoupy M. et al. (2013) The TOMM machinery is a molecular switch in PINK1 and PARK2/PARKIN-dependent mitochondrial clearance. Autophagy 9, 1801–1817.
12. Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V. and Greenamyre J. T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301–1306.
13. Bhattacharyya S., Bakshi R., Logan R., Ascherio A., Macklin E. A. and Schwarzschild M. A. (2016) Oral inosine persistently elevates plasma antioxidant capacity in Parkinson's disease. Mov. Disord. 31, 417–421.
14. Bonifati V., Rizzu P., van Baren M. J. et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256–259.
15. Borland M. K., Trimmer P. A., Rubinstein J. D., Keeney P. M., Mohanakumar K., Liu L. and Bennett J. P. (2008) Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Mol. Neurodegener. 3, 21.
16. Borland M. K., Mohanakumar K. P., Rubinstein J. D., Keeney P. M., Xie J., Capaldi R., Dunham L. D., Trimmer P. A. and Bennett J. P. (2009) Relationships among molecular genetic and respiratory properties of Parkinson's disease cybrid cells show similarities to Parkinson's brain tissues. Biochim. Biophys. Acta 1792, 68–74.
17. Braschi E., Goyon V., Zunino R., Mohanty A., Xu L. and McBride H. M. (2010) Vps35 mediates vesicle transport between the mitochondria and peroxisomes. Curr. Biol. 20, 1310–1315.
18. de Brito O. M. and Scorrano L. (2008) Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 456, 605–610.
19. Brown K. D., Maqsood S., Huang J. Y., Pan Y., Harkcom W., Li W., Sauve A., Verdin E. and Jaffrey S. R. (2014) Activation of SIRT3 by the NAD⁺ precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab. 20, 1059–1068.
20. Burbulla L. F., Schelling C., Kato H. et al. (2010) Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis. Hum. Mol. Genet. 19, 4437–4452.
21. Burns R. S., LeWitt P. A., Ebert M. H., Pakkenberg H. and Kopin I. J. (1985) The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N. Engl. J. Med. 312, 1418–1421.
22. Büttner S., Habernig L., Broeskamp F. et al. (2013) Endonuclease G mediates α-synuclein cytotoxicity during Parkinson's disease. EMBO J. 32, 3041–3054.
23. Casarejos M. J., Menéndez J., Solano R. M., Rodríguez-Navarro J. A., García de Yébenes J. and Mena M. A. (2006) Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J. Neurochem. 97, 934–946.
24. Caviness J. N., Lue L. F., Hentz J. G., Schmitz C. T., Adler C. H., Shill H. A., Sabbagh M. N., Beach T. G. and Walker D. G. (2016) Cortical phosphorylated α-synuclein levels correlate with brain wave spectra in Parkinson's disease. Mov. Disord. 3, 1012–1019.
25. Chan C. S., Guzman J. N., Ilijic E., Mercer J. N., Rick C., Tkatch T., Meredith G. E. and Surmeier D. J. (2007) ‘Rejuvenation’ protects neurons in mouse models of Parkinson's disease. Nature 447, 1081–1086.
26. Charan R. A., Johnson B. N., Zaganelli S., Nardozzi J. D. and LaVoie M. J. (2014) Inhibition of apoptotic Bax translocation to the mitochondria is a central function of parkin. Cell Death Dis. 5, e1313.
27. Chaturvedi R. K. and Beal M. F. (2008) Mitochondrial approaches for neuroprotection. Ann. N. Y. Acad. Sci. 1147, 395–412.
28. Ciron C., Lengacher S., Dusonchet J., Aebischer P. and Schneider B. L. (2012) Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function. Hum. Mol. Genet. 21, 1861–1876.
29. Clark J., Silvaggi J. M., Kiselak T., Zheng K., Clore E. L., Dai Y., Bass C. E. and Simon D. K. (2012) Pgc-1α overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf. PLoS ONE 7, e48925.
30. Cleeter M. W., Chau K. Y., Gluck C. et al. (2013) Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem. Int. 62, 1–7.
31. Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Harper J. D., Williamson R. E. and Lansbury P. T. (2000) Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann. N. Y. Acad. Sci. 920, 42–45.
32. Dai Y., Clark J., Zheng K., Kujoth G. C., Prolla T. A. and Simon D. K. (2014) Somatic mitochondrial DNA mutations do not increase neuronal vulnerability to MPTP in young POLG mutator mice. Neurotoxicol. Teratol. 46, 62–67.
33. Dauer W. and Przedborski S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889–909.
34. Denton R. M. (2009) Regulation of mitochondrial dehydrogenases by calcium ions. Biochim. Biophys. Acta 1787, 1309–1316.
35. Detmer S. A. and Chan D. C. (2007) Functions and dysfunctions of mitochondrial dynamics. Nat. Rev. Mol. Cell Biol. 8, 870–879.
36. Dhungel N., Eleuteri S., Li L. B. et al. (2015) Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on α-synuclein. Neuron 85, 76–87.
37. Di Maio R., Barrett P. J., Hoffman E. K. et al. (2016) α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. Sci. Transl. Med. 8, 342ra378.
38. Dinis-Oliveira R. J., Remião F., Carmo H., Duarte J. A., Navarro A. S., Bastos M. L. and Carvalho F. (2006) Paraquat exposure as an etiological factor of Parkinson's disease. Neurotoxicology 27, 1110–1122.
39. Dong J., Li S., Mo J. L., Cai H. B. and Le W. D. (2016) Nurr1-based therapies for Parkinson's disease. CNS Neurosci. Ther. 22, 351–359.
40. Ekstrand M. I., Terzioglu M., Galter D. et al. (2007) Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl Acad. Sci. USA 104, 1325–1330.
41. Eschbach J., von Einem B., Müller K. et al. (2015) Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization. Ann. Neurol. 77, 15–32.
42. Esteves A. R., Arduíno D. M., Swerdlow R. H., Oliveira C. R. and Cardoso S. M. (2010) Microtubule depolymerization potentiates alpha-synuclein oligomerization. Front. Aging Neurosci. 1, 5.
43. Franco-Iborra S., Vila M. and Perier C. (2016) The Parkinson disease mitochondrial hypothesis: where are we at? Neuroscientist 22, 266–277.
44. Frezza C., Cipolat S., Martins de Brito O. et al. (2006) OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 126, 177–189.
45. Gautier C. A., Kitada T. and Shen J. (2008) Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc. Natl Acad. Sci. USA 105, 11364–11369.
46. Gegg M. E. and Schapira A. H. (2016) Mitochondrial dysfunction associated with glucocerebrosidase deficiency. Neurobiol. Dis. 90, 43–50.
47. Gispert S., Ricciardi F., Kurz A. et al. (2009) Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS ONE 4, e5777.
48. Gollamudi S., Johri A., Calingasan N. Y., Yang L., Elemento O. and Beal M. F. (2012) Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson's disease. PLoS ONE 7, e36191.
49. Greenamyre J. T., MacKenzie G., Peng T. I. and Stephans S. E. (1999) Mitochondrial dysfunction in Parkinson's disease. Biochem. Soc. Symp. 66, 85–97.
50. Greene J. C., Whitworth A. J., Kuo I., Andrews L. A., Feany M. B. and Pallanck L. J. (2003) Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl Acad. Sci. USA 100, 4078–4083.
51. Gu G., Reyes P. E., Golden G. T., Woltjer R. L., Hulette C., Montine T. J. and Zhang J. (2002) Mitochondrial DNA deletions/rearrangements in parkinson disease and related neurodegenerative disorders. J. Neuropathol. Exp. Neurol. 61, 634–639.
52. Guardia-Laguarta C., Area-Gomez E., Rüb C., Liu Y., Magrané J., Becker D., Voos W., Schon E. A. and Przedborski S. (2014) α-Synuclein is localized to mitochondria-associated ER membranes. J. Neurosci. 34, 249–259.
53. Guerreiro P. S., Huang Y., Gysbers A., Cheng D., Gai W. P., Outeiro T. F. and Halliday G. M. (2013) LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models. J. Mol. Med. (Berl) 91, 513–522.
54. Guzman J. N., Sanchez-Padilla J., Wokosin D., Kondapalli J., Ilijic E., Schumacker P. T. and Surmeier D. J. (2010) Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468, 696–700.
55. Hara Y., Yuk F., Puri R., Janssen W. G., Rapp P. R. and Morrison J. H. (2014) Presynaptic mitochondrial morphology in monkey prefrontal cortex correlates with working memory and is improved with estrogen treatment. Proc. Natl Acad. Sci. USA 111, 486–491.
56. Hasegawa K., Yasuda T., Shiraishi C., Fujiwara K., Przedborski S., Mochizuki H. and Yoshikawa K. (2016) Promotion of mitochondrial biogenesis by necdin protects neurons against mitochondrial insults. Nat. Commun. 7, 10943.
57. Hertz N. T., Berthet A., Sos M. L., Thorn K. S., Burlingame A. L., Nakamura K. and Shokat K. M. (2013) A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1. Cell 154, 737–747.
58. Hudson G., Nalls M., Evans J. R. et al. (2013) Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology 80, 2042–2048.
59. Iaccarino C., Crosio C., Vitale C., Sanna G., Carrì M. T. and Barone P. (2007) Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum. Mol. Genet. 16, 1319–1326.
60. Ikebe S., Tanaka M. and Ozawa T. (1995) Point mutations of mitochondrial genome in Parkinson's disease. Brain Res. Mol. Brain Res. 28, 281–295.
61. Imaizumi Y., Okada Y., Akamatsu W. et al. (2012) Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol. Brain 5, 35.
62. Irrcher I., Aleyasin H., Seifert E. L. et al. (2010) Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum. Mol. Genet. 19, 3734–3746.
63. Johri A., Calingasan N. Y., Hennessey T. M., Sharma A., Yang L., Wille E., Chandra A. and Beal M. F. (2012) Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 21, 1124–1137.
64. Keeney P. M., Xie J., Capaldi R. A. and Bennett J. P. (2006) Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 26, 5256–5264.
65. Klivenyi P., Siwek D., Gardian G. et al. (2006) Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol. Dis. 21, 541–548.
66. Kraytsberg Y., Kudryavtseva E., McKee A. C., Geula C., Kowall N. W. and Khrapko K. (2006) Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet. 38, 518–520.
67. Krebiehl G., Ruckerbauer S., Burbulla L. F. et al. (2010) Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. PLoS ONE 5, e9367.
68. Kujoth G. C., Hiona A., Pugh T. D. et al. (2005) Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 309, 481–484.
69. Kuter K., Nowak P., Gołembiowska K. and Ossowska K. (2010) Increased reactive oxygen species production in the brain after repeated low-dose pesticide paraquat exposure in rats. A comparison with peripheral tissues. Neurochem. Res. 35, 1121–1130.
70. Lancaster M. A. and Knoblich J. A. (2014) Generation of cerebral organoids from human pluripotent stem cells. Nat. Protoc. 9, 2329–2340.
71. Langston J. W., Ballard P., Tetrud J. W. and Irwin I. (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979–980.
72. Langston J. W., Forno L. S., Rebert C. S. and Irwin I. (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 292, 390–394.
73. Lavara-Culebras E. and Paricio N. (2007) Drosophila DJ-1 mutants are sensitive to oxidative stress and show reduced lifespan and motor deficits. Gene 400, 158–165.
74. Lesage S., Drouet V., Majounie E. et al. (2016) Loss of VPS13C function in autosomal-recessive parkinsonism causes mitochondrial dysfunction and increases PINK1/Parkin-dependent mitophagy. Am. J. Hum. Genet. 98, 500–513.
75. Lin M. T. and Beal M. F. (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787–795.
76. Lin M. T., Cantuti-Castelvetri I., Zheng K. et al. (2012) Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. Ann. Neurol. 71, 850–854.
77. Lindvall O. (2015) Treatment of Parkinson's disease using cell transplantation. Philos. Trans. R. Soc. Lond. B Biol. Sci. 370, 20140370.
78. Liu G., Zhang C., Yin J. et al. (2009) alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci. Lett. 454, 187–192.
79. Lööv C., Scherzer C. R., Hyman B. T., Breakefield X. O. and Ingelsson M. (2016) α-Synuclein in extracellular vesicles: functional implications and diagnostic opportunities. Cell. Mol. Neurobiol. 36, 437–448.
80. Mandir A. S., Przedborski S., Jackson-Lewis V. et al. (1999) Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc. Natl Acad. Sci. USA 96, 5774–5779.
81. Manning-Bog A. B., McCormack A. L., Li J., Uversky V. N., Fink A. L. and Di Monte D. A. (2002) The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277, 1641–1644.
82. McCormack A. L., Thiruchelvam M., Manning-Bog A. B., Thiffault C., Langston J. W., Cory-Slechta D. A. and Di Monte D. A. (2002) Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 10, 119–127.
83. McNeill A., Magalhaes J., Shen C. et al. (2014) Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137, 1481–1495.
84. Miclea A., Leussink V. I., Hartung H. P., Gold R. and Hoepner R. (2016) Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. J. Neurol. DOI:10.1007/s00415-016-8175-3. [Epub ahead of print]
85. Migdalska-Richards A. and Schapira A. H. (2016) The relationship between glucocerebrosidase mutations and Parkinson disease. J. Neurochem. 139 (Suppl. 1), 77–90.
86. Miller J. D., Ganat Y. M., Kishinevsky S. et al. (2013) Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 13, 691–705.
87. Mudò G., Mäkelä J., Di Liberto V. et al. (2012) Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell. Mol. Life Sci. 69, 1153–1165.
88. Narendra D., Tanaka A., Suen D. F. and Youle R. J. (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795–803.
89. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators (2015) Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 14, 795–803.
90. Okatsu K., Kimura M., Oka T., Tanaka K. and Matsuda N. (2015) Unconventional PINK1 localization to the outer membrane of depolarized mitochondria drives Parkin recruitment. J. Cell Sci. 128, 964–978.
91. Osellame L. D., Rahim A. A., Hargreaves I. P., Gegg M. E., Richard-Londt A., Brandner S., Waddington S. N., Schapira A. H. and Duchen M. R. (2013) Mitochondria and quality control defects in a mouse model of Gaucher disease–links to Parkinson's disease. Cell Metab. 17, 941–953.
92. Ottolini D., Calì T., Negro A. and Brini M. (2013) The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering. Hum. Mol. Genet. 22, 2152–2168.
93. Palacino J. J., Sagi D., Goldberg M. S., Krauss S., Motz C., Wacker M., Klose J. and Shen J. (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279, 18614–18622.
94. Panov A., Dikalov S., Shalbuyeva N., Taylor G., Sherer T. and Greenamyre J. T. (2005) Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J. Biol. Chem. 280, 42026–42035.
95. Parkinson Study Group (2013) Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov. Disord. 28, 1823–1831.
96. Pei L., Mu Y., Leblanc M. et al. (2015) Dependence of hippocampal function on ERRγ-regulated mitochondrial metabolism. Cell Metab. 21, 628–636.
97. Perier C. and Vila M. (2012) Mitochondrial biology and Parkinson's disease. Cold Spring Harb. Perspect Med. 2, a009332.
98. Perier C., Bové J., Dehay B., Jackson-Lewis V., Rabinovitch P. S., Przedborski S. and Vila M. (2010) Apoptosis-inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins. Ann. Neurol. 68, 184–192.
99. Perier C., Bové J. and Vila M. (2012) Mitochondria and programmed cell death in Parkinson's disease: apoptosis and beyond. Antioxid. Redox Signal. 16, 883–895.
100. Perier C., Bender A., García-Arumí E. et al. (2013) Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms. Brain 136, 2369–2378.
101. Pickrell A. M. and Youle R. J. (2015) The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron 85, 257–273.
102. Pickrell A. M., Pinto M., Hida A. and Moraes C. T. (2011) Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurosci. 31, 17649–17658.
103. Ramonet D., Perier C., Recasens A., Dehay B., Bové J., Costa V., Scorrano L. and Vila M. (2013) Optic atrophy 1 mediates mitochondria remodeling and dopaminergic neurodegeneration linked to complex I deficiency. Cell Death Differ. 20, 77–85.
104. Rao V. K., Carlson E. A. and Yan S. S. (2014) Mitochondrial permeability transition pore is a potential drug target for neurodegeneration. Biochim. Biophys. Acta 1842, 1267–1272.
105. Rappold P. M., Cui M., Grima J. C., Fan R. Z., de Mesy-Bentley K. L., Chen L., Zhuang X., Bowers W. J. and Tieu K. (2014) Drp1 inhibition attenuates neurotoxicity and dopamine release deficits in vivo. Nat. Commun. 5, 5244.
106. Ross O. A., Soto A. I., Vilariño-Güell C. et al. (2008) Genetic variation of Omi/HtrA2 and Parkinson's disease. Parkinsonism Relat. Disord. 14, 539–543.
107. Ryan S. D., Dolatabadi N., Chan S. F. et al. (2013) Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription. Cell 155, 1351–1364.
108. Saha S., Guillily M. D., Ferree A. et al. (2009) LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci. 29, 9210–9218.
109. Sanders L. H., McCoy J., Hu X., Mastroberardino P. G., Dickinson B. C., Chang C. J., Chu C. T., Van Houten B. and Greenamyre J. T. (2014) Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease. Neurobiol. Dis. 70, 214–223.
110. Santos D. and Cardoso S. M. (2012) Mitochondrial dynamics and neuronal fate in Parkinson's disease. Mitochondrion 12, 428–437.
111. Scarffe L. A., Stevens D. A., Dawson V. L. and Dawson T. M. (2014) Parkin and PINK1: much more than mitophagy. Trends Neurosci. 37, 315–324.
112. Schwarzschild M. A., Macklin E. A., Ascherio A. and Parkinson Study Group SURE-PD Investigators (2014b) Urate and neuroprotection trials. Lancet Neurol. 13, 758.
113. Shaltouki A., Sivapatham R., Pei Y., Gerencser A. A., Momčilović O., Rao M. S. and Zeng X. (2015) Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines. Stem Cell Reports 4, 847–859.
114. Sherer T. B., Betarbet R., Testa C. M. et al. (2003) Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23, 10756–10764.
115. Shin J. H., Ko H. S., Kang H., Lee Y., Lee Y. I., Pletinkova O., Troconso J. C., Dawson V. L. and Dawson T. M. (2011) PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell 144, 689–702.
116. Sidransky E., Nalls M. A., Aasly J. O. et al. (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361, 1651–1661.
117. Simon D. K. and Johns D. R. (1999) Mitochondrial disorders: clinical and genetic features. Annu. Rev. Med. 50, 111–127.
118. Simon D. K., Lin M. T., Zheng L. et al. (2004) Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiol. Aging 25, 71–81.
119. Simón-Sánchez J. and Singleton A. B. (2008) Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. Hum. Mol. Genet. 17, 1988–1993.
120. Snow B. J., Rolfe F. L., Lockhart M. M. et al. (2010) A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov. Disord. 25, 1670–1674.
121. St-Pierre J., Drori S., Uldry M. et al. (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127, 397–408.
122. Strauss K. M., Martins L. M., Plun-Favreau H. et al. (2005) Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum. Mol. Genet. 14, 2099–2111.
123. Su Y. C., Guo X. and Qi X. (2015) Threonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagy. Biochim. Biophys. Acta 1852, 12–21.
124. 2+ channels. J. Cell Biol. 175, 901–911.
125. Tang F. L., Erion J. R., Tian Y., Liu W., Yin D. M., Ye J., Tang B., Mei L. and Xiong W. C. (2015a) VPS35 in dopamine neurons is required for endosome-to-Golgi retrieval of Lamp2a, a receptor of chaperone-mediated autophagy that is critical for α-synuclein degradation and prevention of pathogenesis of Parkinson's disease. J. Neurosci. 35, 10613–10628.
126. Tang F. L., Liu W., Hu J. X., Erion J. R., Ye J., Mei L. and Xiong W. C. (2015b) VPS35 deficiency or mutation causes dopaminergic neuronal loss by impairing mitochondrial fusion and function. Cell Rep. 12, 1631–1643.
127. Thomas B. and Beal M. F. (2007) Parkinson's disease. Hum. Mol. Genet. 16 Spec No. 2, R183–R194.
128. Thomas B. and Beal M. F. (2010) Mitochondrial therapies for Parkinson's disease. Mov. Disord. 25(Suppl 1), S155–S160.
129. Twig G. and Shirihai O. S. (2011) The interplay between mitochondrial dynamics and mitophagy. Antioxid. Redox Signal. 14, 1939–1951.
130. Valero T. (2014) Mitochondrial biogenesis: pharmacological approaches. Curr. Pharm. Des. 20, 5507–5509.
131. Venderova K. and Park D. S. (2012) Programmed cell death in Parkinson's disease. Cold Spring Harb Perspect Med 2012;2, a009365.
132. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M. and Przedborski S. (2000) Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74, 721–729.
133. Vilariño-Güell C., Wider C., Ross O. A. et al. (2011) VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 89, 162–167.
134. Wang H. L., Chou A. H., Yeh T. H., Li A. H., Chen Y. L., Kuo Y. L., Tsai S. R. and Yu S. T. (2007) PINK1 mutants associated with recessive Parkinson's disease are defective in inhibiting mitochondrial release of cytochrome c. Neurobiol. Dis. 28, 216–226.
135. Wang Y., Dawson V. L. and Dawson T. M. (2009) Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp. Neurol. 218, 193–202.
136. Wang X., Yan M. H., Fujioka H., Liu J., Wilson-Delfosse A., Chen S. G., Perry G., Casadesus G. and Zhu X. (2012) LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum. Mol. Genet. 21, 1931–1944.
137. Yang L., Zhao K., Calingasan N. Y., Luo G., Szeto H. H. and Beal M. F. (2009) Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Antioxid. Redox Signal. 11, 2095–2104.
138. Yue M., Hinkle K. M., Davies P. et al. (2015) Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol. Dis. 78, 172–195.
139. Zanellati M. C., Monti V., Barzaghi C., Reale C., Nardocci N., Albanese A., Valente E. M., Ghezzi D. and Garavaglia B. (2015) Mitochondrial dysfunction in Parkinson disease: evidence in mutant PARK2 fibroblasts. Front. Genet. 6, 78.
140. Zheng B., Liao Z., Locascio J. J. et al. (2010) PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med. 2, 52ra73.
141. Zimprich A., Benet-Pagès A., Struhal W. et al. (2011) A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 89, 168–175.